Heron Therapeutics Inc vs Howmet Aerospace Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Howmet Aerospace Inc trades at $279.19 (market cap $108.82B). The key difference: Howmet Aerospace Inc is far larger — about 1189.8× Heron Therapeutics Inc's market cap, and Howmet Aerospace Inc pays a 0.18% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | HWM | |
|---|---|---|
Market Cap | $91.46M | $108.82B |
Sector | Health | Industrials |
52-Week High | $1.96 | $283.23 |
52-Week Low | $0.39 | $171.00 |
Enterprise Value | $189.36M | $111.07B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.22 exceeding the $1.11 estimate. Financials show robust profitability, including a 20.22% net income margin and 33.98% ROE, though valuation ratios like a P/E of 63.21 appear elevated. Recent news highlights commercial aerospace demand driving growth, with shares gaining 249% since May 2024 according to FXEmpire on July 15, 2026.
The outlook remains positive due to sustained aerospace demand and analyst consensus favoring buys, but risks include high valuation sensitivity and market volatility. Upside to the $317.63 price target offers potential, yet investors should weigh premium multiples against earnings growth momentum and sector cyclicality.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →